A planned registrational phase III trial of AE 37 in patients with breast cancer.
Phase of Trial: Phase III
Latest Information Update: 31 May 2013
At a glance
- Drugs AE 37 (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- 31 May 2013 This trial is being prepared as part of a Special Protocol Assessment (SPA) with the US FDA, according to a Generex Biotechnology Corporation media release.
- 17 Jan 2013 Planned initiation date changed from 1 Jan 2013 to 1 Mar 2013; the FDA will accept submission of a phase III breast cancer trial protocol.
- 03 Jan 2012 Planned initiation date changed from 1 Jun 2013 to 1 Jun 2012, according to a Generex media release.